{"id":"W433802874","doi":"10.1182/blood.v124.21.4410.4410","title":"A Phase II Clinical Trial of Rituximab, Cyclophosphamide, Bortezomib, and Dexamethasone (R-CyBor-D) in Relapsed Low Grade and Mantle Cell Lymphoma","year":2014,"lang":"en","type":"article","venue":"Blood","topic":"Lymphoma Diagnosis and Treatment","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Mantle cell lymphoma; Bortezomib; Rituximab; Internal medicine; Follicular lymphoma; Cyclophosphamide; Gastroenterology; Tolerability; Marginal zone B-cell lymphoma; Multiple myeloma; Oncology; Surgery; Lymphoma; Immunology; Chemotherapy; Adverse effect; B cell","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.002523021,0.001253179,0.001601695,0.0003737037,0.0004383971,0.0009999941,0.0009811103,0.001177747,0.005085479],"category_scores_gemma":[0.001110335,0.0006110723,0.001020999,0.0003624297,0.0009443303,0.0006836731,0.0003980653,0.002648811,0.0009697173],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0008658094,"about_ca_system_score_gemma":0.001746114,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0007544247,"about_ca_topic_score_gemma":0.001827265,"domain_scores_codex":[0.9991995,0.0004939769,0.00004455725,0.0001068579,0.00004666052,0.0001084701],"domain_scores_gemma":[0.9990246,0.0001911446,0.0001403858,0.00007648632,0.00006221521,0.0005051473],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.8688697,0.07101504,0.003251306,0.0005902444,0.0007454124,0.0001928407,0.0001644442,0.0007826115,0.01086426,0.0002793643,0.002750805,0.0404939],"study_design_scores_gemma":[0.7986013,0.1966981,0.002259589,0.0000220899,0.0001418827,0.00007058035,0.00002720397,0.0004230876,0.0007001694,0.000100243,0.0009461418,0.000009619102],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9862434,0.002702817,0.0004688584,0.0007621392,0.0002697899,0.005774979,0.0007766531,0.00007525086,0.002926023],"genre_scores_gemma":[0.9868135,0.001436455,0.001286739,0.001034582,0.0002234066,0.004978853,0.00122911,0.00001103741,0.002986322],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.005085479,"threshold_uncertainty_score":0.0170126,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.02144676874142816,"score_gpt":0.3095067927312773,"score_spread":0.2880600239898491,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}